**Area Drugs and Therapeutics Committee Meeting Minutes**

Wednesday 23rd July 2025 10-12.30pm

Microsoft Teams Meeting

| | | | |
|---|---|---|---|
| | **Present** | | |
| | Veronica Rainey (Chair)<br>Victoria Gemmell (prof Sec)<br>Tyra Smyth<br>Gail Richardson<br>Craig Thurtell<br>Penny Brankin<br>Alistair Brown | Greaem Bryson<br>Kirsty Macfarlane<br>Kelly Baillie<br>Zhuo Min Chong (item 8b)<br>Eimear Gordon<br>Stephanie Dundas<br>Rachael Kelly | |
| **1.** | **Apologies for Absence** | | |
| | Chris Miller, Sharon Murray, David Semple | | |
| **2.** | **Declaration of Interest** | | |
| | Nil | | |
| **3.** | **Ratification of minutes of June 2025 meeting** | | |
| | These were not approved due to the need for a point of clarity. An updated version will be presented at the August meeting for ratification. | | |
| **4.** | **Matters arising not covered elsewhere on the agenda** | | |
| **a.** | **Alteplase Guidance for Patients Requiring Thrombolysis – Alternative to Tenecteplase – Mark Barber / Gary Lynas**<br>Updates made as previously requested. A small point of clarity remained. This will be fed back. The document was approved pending these changes. | | |
| **b.** | **Use of Insulin Pump Systems in Acute Hospitals – Elizabeth McIntyre –** Update Awaited | | |
| **c.** | **Lebrikizumab – Carol Martin - See item 8D** | | |
| **d.** | **Adult Non Obstetric Major Haemorrhage – Andrew Fyfe**<br>Update awaited | | |
| **e.** | **Produodopa Clinical Protocol – Eimear Gordon**<br>Plans are underway for service delivery. Further update will be given at the August meeting. | | |
| **f.** | **Serotonin Syndrome Adult Guideline – Sarah Brady**<br>Update awaited | | |
| **g.** | **Lithium Drug Specific Monitoring Document**<br>Plans are underway for service delivery**.** Once these are in place, the document will be updated and re-presented at this committee. | | |

| | | |
|---|---|---|
| **5.** | **ADTC Committee Business** | |
| **a.** | Draft ToR<br>GB gave an update on feedback received from committee members. A final draft version will be presented at the next meeting. | |
| **6.** | **SMC Advice - CONFIDENTIAL** | **RK** |
| **6.1.a** | **FULL SUBMISSION**<br>Mirikizumab for both SMC approved indications was discussed. It was agreed that an amended communication incorporating the ongoing progress with regional formulary discussions would be put to the IBD team for SMC2822. It was agreed that the expected updated clinical pathway requested to allow the approval for use of SMC2650 would be monitored ongoing as a standing item. | |

| Medicine | Manufacturer | Indication in brief | SMC reference | Advice Summary |
|---|---|---|---|---|
| brentuximab vedotin powder for concentrate for solution for infusion (Adcetris) | Takeda UK Ltd | for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). | SMC2762 | **ACCEPTED with PAS** |
| dupilumab 300 mg solution for injection in pre-filled pen or pre filled syringe (Dupixent) | Sanofi | in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. | SMC2801 | **NOT RECOMMENDED** |

**6.1.b** **FAST TRACK RESUBMISSION**

| Medicine | Manufacturer | Indication in brief | SMC reference | Advice Summary |
|---|---|---|---|---|
| ripretinib tablets (Qinlock) | Deciphera Pharmaceuticals (Netherlands) B.V. | for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. | SMC2821 | **ACCEPTED with PAS** |

**6.1.c** **Deferred Advice**

**Nil**

**6.1.d** **Amended Advice**

pembrolizumab concentrate for solution for infusion (Keytruda®) Merck Sharp & Dohme (UK) Limited SMC2767

abaloparatide solution for injection in pre-filled pen (Eladynos®) Theramex SMC2764

**6.1.e** **ABBREVIATED SUBMISSION**

| Medicine | Manufacturer | Indication in brief | SMC reference | Advice Summary |
|---|---|---|---|---|
| zanubrutinib hard-capsules (Brukinsa) (MCL) | BeiGene | as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. | SMC2819 | **ACCEPTED with PAS** |
| mirikizumab solution for injection in pre-filled pen and concentrate for solution for infusion (Omvoh) | Eli Lilly & Company Ltd | for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. | SMC2822 | **ACCEPTED with PAS** |

**6.1.f** **NON SUBMISSIONS**

| Medicine | Manufacturer | Indication in brief | SMC reference | Advice Summary |
|---|---|---|---|---|
| letermovir film-coated tablets and concentrate for solution for infusion (Prevymis) | Merck Sharp & Dohme (UK) Limited | for prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-]. | SMC2853 | **NOT RECOMMENDED** |
| trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu) | Daiichi Sankyo UK Limited | for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options. | SMC2854 | **NOT RECOMMENDED** |

**6.1.g** **WITHHELD**
**Nil**

**6.1.h** **Resubmission Withdrawn**
efgartigimod alfa (Vyvgart) GlaxoSmithKline SMC2727
Argenx withdrew the resubmission SMC2752 for efgartigimod alfa (Vyvgart), scheduled to be discussed at SMC in July. The advice on the SMC website remains valid, SMC2561 efgartigimod alfa (Vyvgart).

**6.1.i** **Paediatric License Extensions**
These were noted.

**6.1.j** **Collaborative Advice**
Nil

**6.1.k** **Ultra Orphan Update**
This was noted

**6.2** **Updates to NHS LK status on SMC advice**

RK outlined the updated designations for new SMC medicines. This was agreed.

| | | |
|---|---|---|
| **6.3** | **Updates to Lanarkshire Bulletins**<br>RK outlined the updates to bulletins which reflect updated designations for SMC medicines. These were agreed. | |
| **7.** | **Lanarkshire Formulary / West of Scotland Formulary** | **KMc** |
| **7.1.a and 7.1.b** | **NHSLK formulary changes proposals/ Valproate Formulary statement Update (MHRA Drug Safety Update July 2025)**<br>RK provided proposed formulary amendments. This included an update to the formulary statement for Valproate in line with June 25 MHRA drug safety update, as well as a proposal to remove Minocycline from the formulary for rosacea and acne in line with NHS Scotland Government Prescribing Guidance for Medicines of Low or Limited Clinical Value, which was agreed. | |
| **7.2** | **West of Scotland Formulary Updates**<br>KM gave an update on the progress to date of the Regional Formulary. Chapter expert working groups have been formed and discussions will begin to move pathway development forward. There have been some difficulty in getting GP involvement and discussion are ongoing to try and increase participation. A newsletter is in development and will be shared by the Regional team. | |
| **8.** | **Clinical Protocols & Guidelines** | |
| **a.** | **Paediatric Charts – Farhat Mushtaq**<br>This pilot quality improvement (QI) project aims to streamline and standardise paediatric analgesia dosing by transitioning from weight-based to age-based dosing, in line with recent updates to clinical guidance.<br>The committee commended the clarity and layout of the draft posters, noting they were well-designed and easy to interpret. Several recommendations were made, which will fed back to the author.<br>The document was not approved at this time. | |
| **b.** | **Hip Fracture Acute Treatment Pathway – Zhou Min Chong**<br>This is an update to previous version. Some small amendments were requested.<br>The document was approved pending these changes. | |
| **c.** | **Lipid Clinic for High Risk Stroke Patients – Clayton Micallef**<br>Several comments were made which will be fed back to the author.<br>The document was not approved at this time. | |
| **d.** | **Treatment Pathway for the Management of Adults with Moderate to Severe Eczema in Secondary Care – Gillian Chalmers**<br>This is an update to the previous version. This was approved with no further changes. | |
| **e.** | **Sublingual Alfentanil for Early Mobilsation in Hip Fracture Patients**<br>Several comments were made which will be fed back to the author.<br>The document was not approved at this time. | |

| | | |
|---|---|---|
| **f.** | **Chest Wall Injury Analgesia Pathway**<br>There were a number of points raised which will be fed back to the author.<br>Outcome:<br>The document was not approved at this time. Revisions are required as outlined above. | |
| **9.** | **ULM Requests** | |
| **a.** | **ULM – Anakinra – Craig Richardson**<br>The request submitted included both an unlicensed (UL) route and an unlicensed indication.<br>While there were no concerns raised on clinical grounds, the committee requested further clarity on financial implications and regional guidance before proceeding with approval.<br>The request was not approved at this time. | |
| **10.** | **New Medicine Safety Notifications & Alerts** | |
| **a.** | CAS - Home<br>https://www.gov.uk/drug-safety-update<br>This was noted | |
| **b.** | **MHRA Updates – Medicines Safety Roundup June 2025**<br>This was noted | |
| **c.** | **Medicines Related Communications to Health Boards – Graeme Bryson**<br>This is being looked at through Pharmacy Leadership Group. Ongoing progress will be reported. | |
| **d.** | **Bevacizumab Feedback – Lynn Hall**<br>This was noted | |
| **11.** | **Prescribing Management Boards Update** | **GRB** |
| | Reformation of these groups is in progress. Reporting expected in due course. | |
| **12.** | **Medicines for the Treatment of Cancer** | **KB** |
| **12a.** | KB gave an update. There is new SG guidance published July 2025. This supercedes previous guidance and contain a number of key changes. KB will share this. The SACT governace will review and make implementation plans. | |
| **12b** | NCMAG advice. This was noted, and will await regional discussion. | |
| **13.** | **Non-Medical Prescribing** | |
| | Nil | |
| **14.** | **PGD Activity Report** | **RK** |
| a. | **PGD Summary Report – Rachael Kelly**<br>RK provided an update as outlined in the PGD Activity report. Specifically highlighted was three community pharmacy national PGDs which will be three years old in August, for which RK will provide a further update next month. | |

| | | |
|---|---|---|
| b. | **Palliative Care PGD report – Kirsty MacFarlane**<br>This was noted. | |
| **15.** | **Antimicrobial Management Team Update** | **SD** |
| | Nil | |
| **16.** | **Lay member related items** | |
| | Nil | |
| **17.** | **Correspondence** | |
| **a.** | **ADTCC Newsletter**<br>For noting | |
| **b.** | **Puberty Supressing Hormones – Graeme Bryson**<br>This was noted and a request made for onward sharing with Communiy Pharmacy. | |
| **18.** | **AOCB** | |
| **a.** | **Launch of Consultation on Revised Polypharmacy Guidelines – Graeme Bryson**<br><br>Polypharmacy Guidance: appropriate prescribing, making medicines safe, effective and sustainable 2025 - 2028 - Scottish Government consultations - Citizen Space<br><br>There was a discussion around distribution and if individual or a Board response would be more appropriate. Consultation closes 22/9/25.<br><br>VR agreed to co-ordinate distribution and response. | |
| **b.** | **HEPMA Upgrade Gail Richardson**<br><br>The has been rescheduled to 13th August 2025. This will result in a number of hours offline overnight. There will be extensive communications and plans put in place to ensure urgent medicines can be prescribed during this period. This was noted. | |
| **c.** | **ScotStar calculator Gail Richardson**<br><br>Drug calculators now require a licence as per MHRA requirements. The ScotStar calculator is currently used to calculate weight-based drug doses for children in arrest or peri-arrest situations. It is likely to be affected by this change. This will have implications for paediatric calculations in emergency situations across all 3 acute sites. Ther are no alternative calculators available at present. This issue will be raised at the national SNAPP meeting, and will be discussed by GRB with the Chris Deigan. PB will also contact the Scottish Resusitation Group. | |
| **19.** | **Date of Next Meeting** | |
| | Wednesday 20th August 2025 10-12.30pm<br>MS TEAMS | |